Hematology and Oncology - Internal Medicine - Laboratories | Nagoya University GraduateSchool of Medicine

Laboratories

Back
Top > Laboratories > Internal Medicine > Hematology and Oncology

Internal MedicineHematology and Oncology

Introduction

Hematopoietic organs (bone marrow), blood vessels, blood, spleen, thymus, lymph nodes and other tissues form an extremely close network in the body, and play important roles in keeping vital activities. Blood is simple to collect and easy to handle in test tubes, and thus has been used as a subject for research since old times. In the Hematology and Oncology department, we are working intensely on our mission to elucidate the pathological conditions of patients and to develop and establish novel treatments for patients by using various techniques from fields such as cell biology, biochemistry, genetic engineering, molecular biology and drug development.
The department has achieved results in a wide range of advanced research fields, including analysis of molecular mechanisms related to the onset of leukemia and malignant lymphoma, development of novel molecular targeted therapies, overcoming drug resistance to molecularly targeted drugs, and transplant immunology to improve results in hematopoietic stem cell transplantation.
The department got its start when the hematology group of the former First Department of Internal Medicine became independent. The former First Department of Internal Medicine was established in the Taisho Era (1912-1926), with Professor Seizo Katsunuma, known as the founder of the Japanese Society of Hematology, serving as the first professor. He was succeeded by Prof. Susumu Hibino, Prof. Itsuro Sobue, Prof. Hidehiko Saito and Prof. Tomoki Naoe, and the department developed with a history and tradition not only in hematology, but in internal medicine.
In the university hospital, we are in charge of the hematology ward, working to treat hematological malignancies (e.g., leukemia, lymphoma, myeloma), hematopoietic disorders (e.g., aplastic anemia), coagulation disorders (hemophilia, von Willebrand disease, etc.), and other diseases. The department currently has 16 graduate students in the doctoral course. Many people study overseas after graduating from the program; currently 3 members are studying in the United States. Of the 24 members, 8 have studied in other countries.

Research Projects

The Department of Hematology and Oncology works closely with domestic and overseas laboratories to actively advance research in the following main areas.

(1) Clinical research group (Prof. Kiyoi, Associate Prof. Murata, Associate Prof. Hayakawa, Associate Prof. Shimada, Assistant Prof. Nishida, Assistant Prof. Terakura, Assistant Prof. Ishikawa, Assistant Prof. Ushijima, Assistant Prof. Goto)

This clinical research group actively participates multi-center clinical trials to develop new treatment for hematological malignancies. We are a member of Japan Adult Leukemia Study Group (JALSG) and the Japan Clinical Oncology Group (JCOG). And we also conduct multicenter research as a member of the Nagoya Blood and Marrow Transplantation Group (NBMTG), and nationwide retrospective studies in the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

(2) Analyzing molecular pathogenesis/target therapy development group (Prof. Kiyoi, Associate Prof. Hayakawa, Associate Prof. Shimada, Assistant Prof. Ishikawa, Assistant Prof. Ushijima)

We investigate molecular pathology of hematological malignancies such as acute leukemia, myelodysplastic syndrome, and malignant lymphoma and develop novel therapies for them. We search for molecular targets for anti-cancer therapy through comprehensive gene analyses by next generation sequencer and analyses of patient-derived xenograft (PDX) that was established by transplanting patient tumor cells into mice. We also work together with pharmaceutical companies in the preclinical development of molecularly targeted drugs.

(3) Immunotherapy development group (Associate Prof. Murata, Assistant Prof. Nishida, Assistant Prof. Terakura, Assistant Prof. Goto)

Basic research in this group is focused on overcoming post-transplantation complications such as GVHD and viral infections, increasing the GVL effect, and developing of gene therapy using chimeric antigen receptor. We also aim to develop novel transplantation and immunotherapy through clinical research on “intra-bone marrow transplantation of cord blood” “application of MSC for transplantation” and “viral-specific CTL therapy”.

(4) Thrombosis and Hemostasis group (Blood Transfusion Dept.:Prof. Matsushita, Assistant Prof. Suzuki, Assistant Prof. Kishimoto)

This group studies the mechanisms of congenital and acquired bleeding disorders and thrombotic factors. We also develop and analyze original murine models which mimic human disorders, von Willebrand disease, MYH9 disorders and prothrombin disorders etc.

Faculty Members

FacultyPositionDepartment
Hitoshi Kiyoi Professor Hematology and Oncology
Makoto Murata Associate Professor Hematology and Oncology
Fumihiko Hayakawa Lecturer Hematology and Oncology
Kazuyuki Shimada Lecturer Hematology and Oncology
Tetsuya Nishida Assistant Professor Hematology and Oncology
Seitaro Terakura Assistant Professor Hematology and Oncology
Yuichi Ishikawa Assistant Professor Hematology and Oncology
Tatsunori Goto Assistant Professor Hematology and Oncology
Yoko Ushijima Assistant Professor Center for Postgraduate Clinical Training and Career Development / Hematology and Oncology

Bibliography

  • 2016
    1. Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. J Immunother, 2016 Oct;39(8):306-15.
    2. Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. Haemophilia, 2016.Oct.
    3. Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer Sci, 2016 Sep;107(9):1270-80.
    4. Suzuki Y, Tomita A, Nakamura F, Iriyama C, Shirahata-Adachi M, Shimada K, Akashi A, Ishikawa Y, Kaneda N, Kiyoi H. Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes. Cancer Sci, 2016 Sep;107(9):1329-37.
    5. Niwa Y, Minami Y, Abe A, Hayakawa F, Yamada K, Naoe T. Wnt signaling is associated with cell survival in the interaction between acute myeloid leukemia cells and stromal cells. Leuke lymphoma,2016 Sep;57(9):2192-4.
    6. Morishita T, Hayakawa F, Sugimoto K, Iwase M, Yamamoto H, Hirano D, Kojima Y, Imoto N, Naoe T, Kiyoi H. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget, 2016.Aug.
    7. Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, Murata M, Kiyoi H. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. Cancer Immunol Res, 2016 Aug;4(8):658-68.
    8. Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, Kiyoi H, Naoe T. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci, 2016.Jul.
    9. Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, Hirakawa A, Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H. Development and analysis of patient derived xenograft mouse models in intravascular large B-cell lymphoma. Leukemia, 2016 Jul;30(7):1568-79.
    10. Inagaki Y, Hayakawa F, Hirano D, Kojima Y, Morishita T, Yasuda T, Naoe T, Kiyoi H. PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: A mechanism for antigen-triggered plasma cell differentiation. Biochem Biophys Res Commun, 2016 Jun;475(2):176-81.
    11. Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget, 2016 Jun.
    12. Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet, 2016 May;48(5):569-74.
    13. Imoto N, Hayakawa F, Kurahashi S, Morishita T, Kojima Y, Yasuda T, Sugimoto K, Tsuzuki S, Naoe T, Kiyoi H. BLNK is a selective target of repression by PAX5-PML in the differentiation block that leads to the development of acute lymphoblastic leukemia. J Biol Chem, 2016 Feb;291(9):4723-31.
    14. Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, Najima Y,
    15. Fukuda T, Uchida N, Takahashi S, Nagamura-Inoue T, Morishima Y, Miyamura K; Japan Society for Hematopoietic Cell Transplantation. Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit
    16. Cord Blood Transplantation in Adults with Acute Leukemia. Biol Blood Marrow Transplant, 2016 Feb;22(2):330-8.
    17. Kishimoto M, Suzuki N, Murata M, Ogawa M, Kanematsu T, Takagi A, Kiyoi H, Kojima T, Matsushita T. The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese. Ann Hematol, 2016 Feb;95(3):541-2.
    18. Kanematsu T, Suzuki N, Yoshida T, Kishimoto M, Aoki T, Ogawa M, Kagami Y, Kiyoi H, Matsushita T, Kunishima S. A case of MYH9 disorders caused by a novel mutation (p.K74E). Ann Hematol, 2016 Jan;95(1):161-3.
    19. Miyao K, Sawa M, Kuwatsuka Y, Ozawa Y, Kato T, Kohno A, Sao H, Nishida T, Iida H, Naito K, Tsurumi H, Taji H, Mizuta S, Kusumoto S, Nakase K, Morishita Y, Kawashima N, Miyamura K, Murata M. Influence of melphalan plus fludarabine- conditioning regimen in elderly patients aged ≥ 55 years with hematological malignancies.\tBone Marrow Transplant, 2016 Jan;51(1):157-60.
  • 2015
    1. Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, Takizawa J, Mitani K, Igarashi T, Sakai K, Miyazaki K, Mihara K, Ohmachi K, Nakamura N, Takasaki H, Kiyoi H, Nakamura S, Kinoshita T, Ogura M. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J, 2015 Dec;5:e372.
    2. Hanajiri R, Murata M, Sugimoto K, Murase M, Sakemura R, Goto T, Watanabe K, Imahashi N, Terakura S, Ohashi H, Akatsuka Y, Kurahashi S, Miyamura K, Kiyoi H, Nishida T, Naoe T. Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection. Bone Marrow Transplant, 2015 Sep;50(9):1187-94.
    3. Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T. The features of clearance in recombinant factor IX (BeneFIX(®)). Haemophilia. 2015 Sep;21(5):702-7.
    4. Sugimoto K, Hayakawa F, Shimada S, Morishita T, Shimada K, Katakai T, Tomita A, Kiyoi H, Naoe T. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci Rep, 2015 Aug;5:13054.
    5. Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Sawa M, Yokohata E, Kurahashi S, Ozawa Y, Nishida T, Kiyoi H, Watamoto K, Kohno A, Kasai M, Kato C, Iida H, Naoe T, Miyamura K, Murata M; for the Nagoya Blood and Marrow Transplantation Group. Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. Ann Hematol, 2015 Jul;94(7):1139-48.
    6. Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, Murata M. Simple and Efficient Generation of Virus-specific T Cells for Adoptive Therapy Using Anti-4-1BB Antibody. J Immunother, 2015 Feb-Mar;38(2):62-70.
    7. Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M. Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells. J Immunol, 2015 Feb;194(3): 911-20.
  • 2014
    1. Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, Igarashi T, Maeda Y, Fukuhara N, Ishida F, Niitsu N, Ohmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Ogura M. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica, 2014 Dec;99(12):1817-25.
    2. Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suenobu S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG). Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J, 2014 Oct;4:e252.
    3. Kishimoto M, Matsuda T, Yanase S, Katsumi A, Suzuki N, Ikejiri M, Takagi A, Ikawa M, Kojima T, Kunishima S, Kiyoi H, Naoe T, Matsushita T, Maruyama M. Rhof promotes murine marginal zone B cell development. Nagoya J Med Sci, 2014 Aug;76(3-4):293-305.
    4. Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia, 2014 Aug;28(8):1586-95.
    5. Shimada K, Tomita A, Saito S, Kiyoi H. Effectiveness of ofatumumab to rituximab resistant CLL/SLL cells with reduced CD20 protein expression. Br J Haematol, 2014 Aug;166(3):455-7.
    6. Terakura S, Nishida T, Inamoto Y, Ohashi H, Naoe T, Murata M. Successful unrelated cord blood transplantation for adult acquired aplastic anemia using reduced intensity conditioning without ATG. Immunol Lett, 2014 Jul;160(1):99-101.
    7. Nishiwaki S, Nakayama T, Murata M, Nishida T, Terakura S, Saito S, Kato T, Mizuno H, Imahashi N, Seto A, Ozawa Y, Miyamura K, Ito M, Takeshita K, Kato H, Toyokuni S, Nagao K, Ueda R, Naoe T. Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions. PLoS One, 2014 May; 9(5):e96252.
    8. Kato T, Nishida T, Ito Y, Murase M, Murata M, Naoe T. Correlations of programmed death 1 expression and serum IL-6 level with exhaustion of cytomegalovirus-specific T cells after allogeneic hematopoietic stem cell transplantation. Cell Immunol, 2014 Mar-Apr;288(1-2):53-59.
    9. Murata M, Nishida T, Taniguchi S, Ohashi K, Ogawa H, Fukuda T, Mori T, Kobayashi H, Nakaseko C, Yamagata N, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Suzuki R, Naoe T. Allogeneic transplantation for primary myelofibrosis with bone marrow, peripheral blood, or umbilical cord blood: An analysis of the JSHCT. Bone Marrow Transplant, 2014 Mar;49(3):355-60.
    10. Yasuda T, Ueno T, Fukumura K, Yamato A, Ando M, Yamaguchi H, Soda M, Kawazu M, Sai E, Yamashita Y, Murata M, Kiyoi H, Naoe T, Mano H. Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia, 2014 Feb;28(2):426-8.
    11. Tokunaga T, Tomita A, Sugimoto K, Shimada K, Iriyama C, Hirose T, Shirahata-Adachi M, Suzuki Y, Mizuno H, Kiyoi H, Asano N, Nakamura S, Kinoshita T, Naoe T.\tDe novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci, 2014 Jan;105(1):35-43.
  • 2013
    1. Imahashi N, Nishida T, Ito Y, Kawada JI, Nakazawa Y, Toji S, Suzuki S, Terakura S, Kato T, Murata M, Naoe T. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.\tMol Immunol, 2013 Dec;56(4):399-405.
    2. Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S, Naoe T.\t A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J, 2013 Nov;3:e166.
    3. Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Mori T, Taniguchi S, Eto T, Ohashi K, Hino M, Inoue M, Ogawa H, Atsuta Y, Nagamura-Inoue T, Yabe H, Morishima Y, Sakamaki H, Suzuki R. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD working group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 2013 Aug;19(8):1183-9.
    4. Suzuki N, Kunishima S, Ikejiri M, Maruyama S, Sone M, Takagi A, Ikawa M, Okabe M, Kojima T, Saito H, Naoe T, Matsushita T. Establishment of Mouse Model of MYH9 Disorders: Heterozygous R702C Mutation Provokes Macrothrombocytopenia with Leukocyte Inclusion Bodies, Renal Glomerulosclerosis and Hearing Disability. PLoS One, 2013 Aug;8(8):e71187.
    5. Niimi K, Kiyoi H, Ishikawa Y, Hayakawa F, Kurahashi S, Kihara R, Tomita A, Naoe T. GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. Leukemia Research Reports, 2013 Mar 19;2(1):21-5.
    6. Yasuda T, Suzuki R, Ishikawa Y, Terakura S, Inamoto Y, Yanada M, Nagai H, Ozawa Y, Ozeki K, Atsuta Y, Emi N, Naoe T. Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies. Int J Infect Dis, 2013 Jun;17(6):e385-90.
    7. Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol\t, 2013 Jun;97(6):717-25.
  • 2012
    1. Mizuno H, Nakayama T, Miyata Y, Saito S, Nishiwaki S, Nakao N, Takeshita K, Naoe T. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia, 2012 Oct;26(10):2269-76.
    2. Minami Y, Abe A, Minami M, Kitamura K, Hiraga J, Mizuno S, Ymamoto K, Sawa M, Inagaki Y, Miyamura K, Naoe T. Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors. Leukemia, 2012 Sep;26(9):2142-3.
    3. Kuwatsuka Y, Kohno A, Terakura S, Saito S, Shimada K, Yasuda T, Inamoto Y, Miyamura K, Sawa M, Murata M, Karasuno T, Taniguchi S, Nagafuji K, Atsuta Y, Suzuki R, Fukumoto M, Naoe T, Morishita Y; Nagoya Blood and Marrow Transplantation Group. Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.Cancer Sci, 2012 Sep;103(9):1688-94.
    4. Shimada K, Tomita A, Minami Y, Abe A, Hind CK, Kiyoi H, Cragg MS, Naoe T. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. Exp Hematol, 2012 Sep;40(9):724-737.
    5. Nishiwaki S, Nakayama T, Saito S, Mizuno H, Ozaki T, Takahashi Y, Maruyama S, Nishida T, Murata M, Kojima S, Naoe T. Efficacy and safety of human adipose tissue-derived mesenchymal stem cells for supporting hematopoiesis. Int J Hematol, 2012 Sep;96(3):295-300.
    6. Sugimoto T, Tomita A, Abe A, Iriyama C, Kiyoi H, Naoe T. Chimeric antisense RNA derived from chromosomal translocation modulates target gene expression. Haematologica, 2012 Aug;97(8):1278-80.
    7. Tomita A, Shirasugi Y, Ito T, Tsurumi H, Naoe T. Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria. Ann Hematol, 2012 Jul;91(7):1139-41.
    8. Watanabe K, Minami Y, Ozawa Y, Miyamura K, Naoe T. T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports. Anticancer Res, 2012 May;32(5):1779-83.
    9. Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T. Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin. Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T. Eur J Haematol, 2012 Apr;88(4):314-20.
    10. Nishiwaki S, Nakayama T, Murata M, Nishida T, Sugimoto K, Saito S, Kato T, Mizuno H, Imahashi N, Seto A, Ozawa Y, Goto T, Koyama D, Yokohata E, Kubota N, Kamoshita S, Miyamura K, Matsumoto K, Ito M, Naoe T. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. Int J Hematol, 2012 Apr;95(4):428-33.
    11. Kato T, Terakura S, Murata M, Sugimoto K, Murase M, Iriyama C, Tomita A, Abe A, Suzuki M, Nishida T, Naoe T. Escape of leukemia blasts from HLA-specific CTL pressure in a recipient of HLA one locus-mismatched bone marrow transplantation. Cell Immunol, 2012 Mar-Apr;276(1-2):75-82.
    12. Iriyama C, Tomita A, Hoshino H, Adachi-Shirahata M, Furukawa-Hibi Y, Yamada K, Kiyoi H, Naoe T. Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. Biochem Biophys Res Commun, 2012 Mar 23;419(4):662-9.
    13. Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, Tanimoto M, Iwasaki T, Isoda A, Sakai A, Kobayashi H, Kitamura K, Matsue K, Taniwaki M, Tamashima S, Saburi Y, Masunari T, Naoe T, Nakamura S, Kinoshita T. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood, 2012 Mar 22;119(12):2837-43.
    14. Yasuda T, Hayakawa F, Kurahashi S, Sugimoto K, Minami Y, Tomita A, Naoe T. B cell receptor-ERK1/2 signal cancels PAX5-dependent repression of BLIMP1 through PAX5 phosphorylation: a mechanism of antigen-triggering plasma cell differentiation. J Immunol, 2012 Jun 15;188(12):6127-34.
  • 2011
    1. Murase M, Nishida T, Onizuka M, Inamoto Y, Sugimoto K, Imahashi N, Murata M, Miyamura K, Kodera Y, Inoko H, Naoe T. Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT. Bone Marrow Transplant, 2011 Nov;46(11):1444-9.
    2. Saito S, Nakayama T, Hashimoto N, Miyata Y, Egashira K, Nakao N, Nishiwaki S, Hasegawa M, Hasegawa Y, Naoe T. Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. Am J Pathol, 2011 Sep;179(3):1088-94.
    3. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 2011 Aug 11;118(6):1600-9.
    4. Terakura S, Atsuta Y, Sawa M, Ohashi H, Kato T, Nishiwaki S, Imahashi N, Yasuda T, Murata M, Miyamura K, Suzuki R, Naoe T, Ito T, Morishita Y. A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. Ann Oncol. 2011 Aug;22(8):1865-71.
    5. Ishikawa Y, Kiyoi H, Naoe T. Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. Leukemia Res, 2011 May;35(5):685-8.
    6. Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, Abe A, Naoe T. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene, 2011 Apr 14;30(15):1822-30.
    7. Katsumi A, Kiyoi H, Abe A, Tanizaki R, Iwasaki T, Kobayashi M, Matsushita T, Senga T, Kohno T, Kojima T, Kaibuchi K, Hamaguchi M, Naoe T. FLT3/ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signaling. Eur J Haematol, 2011 Mar;86(3):191-8.
    8. Sakai K, Ishikawa Y, Mori Y, Kobayashi M, Iriyama C, Ozawa Y, Suzuki T, Minami Y, Ishikawa K, Kaneda N, Naoe T, Kiyoi H. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib-resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. Int J Hematol, 2011 Feb;93(2):237-42.
  • 2010
    1. Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T. Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia. Int J Hematol, 2010 Nov;92(4):624-33.
    2. Minami Y, Kajiguchi T, Abe A, Ohno T, Kiyoi H, Naoe T. Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment. Int J Hematol, 2010 Nov;92(4):664-6.
    3. Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K, Kohno A, Sugiura I, Yokozawa T, Hanamura A, Yamamoto K, Iida H, Emi N, Suzuki R, Ohnishi K, Naoe T. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci, 2010 Oct;101(10):2186-92.
    4. Nakao N, Nakayama T, Yahata T, Muguruma Y, Saito S, Miyata Y, Yamamoto K, Naoe T. Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Am J Pathol, 2010 Aug;177(2):547-54.
    5. Suzuki M, Abe A, Imagama S, Nomura Y, Tanizaki R, Minami Y, Hayakawa F, Ito Y, Katsumi A, Yamamoto K, Emi N, Kiyoi H, Naoe T. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol, 2010 Mar;84(3):229-38.
    6. Tanizaki R, Nomura Y, Miyata Y, Minami Y, Abe A, Hanamura A, Sawa M, Murata M, Kiyoi H, Matsushita T, Naoe T. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rgammac-/- mice. Cancer Sci, 2010 Mar;101(3):631-8.
    7. Inamoto Y, Murata M, Katsumi A, Kuwatsuka Y, Tsujimura A, Ishikawa Y, Sugimoto K, Onizuka M, Terakura S, Nishida T, Kanie T, Taji H, Iida H, Suzuki R, Abe A, Kiyoi H, Matsushita T, Miyamura K, Kodera Y, Naoe T. Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. Bone Marrow Transplant, 2010 Feb;45(2):363-9.
    8. Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, Niitsu N, Miwa H, Asaoku H, Kosugi H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamamoto K, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T; IVL Study Group in Japan. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci, 2010 Jun;101(6):1480-6.

Research Keywords

leukemia、malignant lymphoma、multiple myeloma、myelodysplastic syndrome、aplastic anemia、hemolytic anemia、idiopathic thrombocytopenic purpura、hemophilia、von Willebrand disease、Gene mutations、chromosomal abnormalities、molecularly targeted drugs、kinase inhibitors、antibody therapeutic drugs、immunotherapy、transplantation immunity、differentiation-inducing therapy、epigenetics

Recruitment of students to the master’s and doctoral courses

 In the Department of Hematology and Oncology, we aim to advance understanding of molecular pathology in blood disease, develop new diagnostic and treatment methods, and promote high quality clinical research that can be used in evidence-based medicine. The Department’s graduate students work intensely to produce original research findings to present to the world with the ultimate goal of enabling patients to regain their health. Each project is executed together with a project leader who possesses advanced research skills, and we have a system to provide consistent guidance from carrying out the research to publishing the results. We are recruiting graduate students who move these researches forward. People with interest in the master’s and doctoral courses in the Department of Hematology and Oncology are encouraged to contact us. Program tours are available as needed.